Dr Parkinson’s Publications

Publications

  1. Parkinson JF, Sekhon LHS
    Surgical Management of Spinal Epidural Abscess: Selection of Approach Based on MRI Appearance
    Journal of Clinical Neuroscience 11:130-133, 2004 Feb
  2. Parkinson JF, Sekhon LHS
    Cervical Arthroplasty Complicated By Delayed Spontaneous Fusion Case Report
    Journal of Neurosurgery (Spine) 2(3):377-80, 2005 Mar
  3. Parkinson JF, Sekhon LHS
    Cervical arthroplasty for the treatment of cervical spine disease
    Australasian Musculoskeletal Medicine 9:28-31, 2004
  4. Parkinson JF, Sekhon LHS
    Surgical Management of Spinal Epidural Abscess: Selection of Approach Based on MRI Appearance
    Journal of Clinical Neuroscience 11:130-133, 2004 Feb
  5. Parkinson JF, Sekhon LHS
    Cervical Arthroplasty Complicated By Delayed Spontaneous Fusion Case Report
    Journal of Neurosurgery (Spine) 2(3):377-80, 2005 Mar
  6. Parkinson JF, Sekhon LHS
    Cervical arthroplasty for the treatment of cervical spine disease
    Australasian Musculoskeletal Medicine 9:28-31, 2004
  7. Parkinson JF, Sekhon LHS
    Spinal epidural abscess: appearance on magnetic resonance imaging as a guide to surgical management
    Neurosurgical Focus 17:E12, 2004
  8. McDonald K, Parkinson J, Wheeler H et al.
    Identification of gene /protein sets that discriminate high grade gliomas from low grade
    Neuro-Oncology 8(4):423-423, 2006 Oct (Abstract)
  9. McDonald KL, Parkinson JF, Wheeler HR et al
    Methylation of MGMT promoter in glioblastoma – Correlation between methylation-specific PCR, sequencing, and mRNA expression
    Neuro-Oncology 8(4):461-461, 2006 Oct (Abstract)
  10. Parkinson JF, McDonald KL, Wheeler H, et al
    Variation in methylation status of MGMT promoter in serial glioblastoma specimens
    Neuro-Oncology 8(4):461-462, 2006 Oct (Abstract)
  11. McDonald KL, O’Sullivan MG, Parkinson JF et al
    IQGAP1 and IGFBP2: valuable biomarkers for determining prognosis in glioma patients
    Journal of Neuropathology and Experimental Neurology 66(5):405-17, 2007 May
  12. McDonald K, O’Sullivan M, Parkinson J, et al.
    IQGAP1 and IGFBP2: Valuable biomarkers for determining prognosis in glioma patients
    Neuro-Oncology 9(4):541-541, 2007 Oct (Abstract)
  13. Parkinson JF, Wheeler HR, McDonald KL
    Contribution of DNA repair mechanisms to determining chemotherapy response in high-grade glioma
    Journal of Clinical Neuroscience 15(1):1-8, 2008 Jan
  14. Parkinson JF, Wheeler HR, Clarkson A et al.
    Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma
    Journal of Neuro-oncology 87(1):71-8, 2008 Mar
  15. Payne CA, Maleki S, Messina M, O’Sullivan MG, Stone G, Hall NR, Parkinson JF et al.
    Loss of Prostaglandin D2 Synthase: A key molecular event in the transition of a low grade astrocytoma to an anaplastic astrocytoma
    Molecular Cancer Therapeutics 7(10):3420-8, 2008 Oct
  16. Tacon LJ, Parkinson JF, Hudson BJ et al.
    Headache of a diagnosis: frontotemporal pain and inflammation associated with osteolysis.
    Medical Journal of Australia 189(10):591-2, 2008 Nov 17
  17. Li D, Brennan JW, Buckland, ME, Parkinson JF
    Bronchogenic Carcinoid Metastasis to the Intramedullary Spinal Cord
    Journal of Clinical Neuroscience, 17(9):1196-98, 2010 Sept
  18. Parkinson JF, Afaghi V, Payne CA et al.
    The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20 years experience at a single centre
    Journal of Clinical Neuroscience, 18(3):329-33, 2011 March
  19. Tan KL, Parkinson JF, McGee-Collett MG, Buckland ME
    Spinal intradural malignant peripheral nerve sheath tumour
    Pathology, 43(3):278-80, 2011 April
  20. Sevim H, Parkinson JF, McDonald KL
    Etoposide-mediated glioblastoma cell death: dependent or independent on the expression of its target, topoisomerase II alpha?
    Journal of Cancer Research and Clinical Oncology 137(11):1705-12, 2011 November
  21. Parker NR, Khong P, Parkinson JF, Howell VM, Wheeler HR.
    Molecular heterogeneity in glioblastoma: potential clinical implications.
    Frontiers in Oncology 5:55, 2015 Mar 3
  22. Chan DL, Schembri G, Back M, Bailey DL, Roach PJ, Wheeler H, Cook R, Parkinson J, Lee A, Jayamanne D, Drummond J, Hsiao E.
    FET PET in the evaluation of indeterminate brain lesions on MRI: differentiating glioma from other non-neoplastic causes.
    European Journal of Nuclear Medicine and Molecular Imaging 42:S603, 2015 Oct (Abstract)
  23. Parker NR, Hudson AL, Khong P, Parkinson JF, Dwight T, Ikin RJ, Zhu Y, Cheng ZJ, Vafaee F, Chen J, Wheeler HR, Howell VM.
    Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma.
    Scientific Reports 6:22477, 2016 Mar 4
  24. French H, Somasundaram A, Biggs M, Parkinson J, Allan R, Ball J, Little N.
    Idiopathic intradural dorsal thoracic arachnoid cysts: A case series and review of the literature.
    Journal of Clinical Neuroscience 40:147-152, 2017 Jun
  25. Harris G, Jayamanne D, Wheeler H, Gzell C, Kastelan M, Schembri G, Brazier D, Cook R, Parkinson J, Khasraw M, Louw S, Back M.
    Survival outcome of elderly patients with Glioblastoma Multiforme in their seventy fifth year or older treated with adjuvant therapy.
    International Journal of Radiation Oncology*Biology*Physics In press, Published online 2017 Feb 20
  26. Parkinson JF, Sekhon LHS
    Spinal epidural abscess: appearance on magnetic resonance imaging as a guide to surgical management
    Neurosurgical Focus 17:E12, 2004
  27. McDonald K, Parkinson J, Wheeler H et al.
    Identification of gene /protein sets that discriminate high grade gliomas from low grade
    Neuro-Oncology 8(4):423-423, 2006 Oct (Abstract)
  28. McDonald KL, Parkinson JF, Wheeler HR et al
    Methylation of MGMT promoter in glioblastoma – Correlation between methylation-specific PCR, sequencing, and mRNA expression
    Neuro-Oncology 8(4):461-461, 2006 Oct (Abstract)
  29. Parkinson JF, McDonald KL, Wheeler H, et al
    Variation in methylation status of MGMT promoter in serial glioblastoma specimens
    Neuro-Oncology 8(4):461-462, 2006 Oct (Abstract)
  30. McDonald KL, O’Sullivan MG, Parkinson JF et al
    IQGAP1 and IGFBP2: valuable biomarkers for determining prognosis in glioma patients
    Journal of Neuropathology and Experimental Neurology 66(5):405-17, 2007 May
  31. McDonald K, O’Sullivan M, Parkinson J, et al.
    IQGAP1 and IGFBP2: Valuable biomarkers for determining prognosis in glioma patients
    Neuro-Oncology 9(4):541-541, 2007 Oct (Abstract)
  32. Parkinson JF, Wheeler HR, McDonald KL
    Contribution of DNA repair mechanisms to determining chemotherapy response in high-grade glioma
    Journal of Clinical Neuroscience 15(1):1-8, 2008 Jan
  33. Parkinson JF, Wheeler HR, Clarkson A et al.
    Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma
    Journal of Neuro-oncology 87(1):71-8, 2008 Mar
  34. Payne CA, Maleki S, Messina M, O’Sullivan MG, Stone G, Hall NR, Parkinson JF et al.
    Loss of Prostaglandin D2 Synthase: A key molecular event in the transition of a low grade astrocytoma to an anaplastic astrocytoma
    Molecular Cancer Therapeutics 7(10):3420-8, 2008 Oct
  35. Tacon LJ, Parkinson JF, Hudson BJ et al.
    Headache of a diagnosis: frontotemporal pain and inflammation associated with osteolysis.
    Medical Journal of Australia 189(10):591-2, 2008 Nov 17
  36. Li D, Brennan JW, Buckland, ME, Parkinson JF
    Bronchogenic Carcinoid Metastasis to the Intramedullary Spinal Cord
    Journal of Clinical Neuroscience, 17(9):1196-98, 2010 Sept
  37. Parkinson JF, Afaghi V, Payne CA et al.
    The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20 years experience at a single centre
    Journal of Clinical Neuroscience, 18(3):329-33, 2011 March
  38. Tan KL, Parkinson JF, McGee-Collett MG, Buckland ME
    Spinal intradural malignant peripheral nerve sheath tumour
    Pathology, 43(3):278-80, 2011 April
  39. Sevim H, Parkinson JF, McDonald KL
    Etoposide-mediated glioblastoma cell death: dependent or independent on the expression of its target, topoisomerase II alpha?
    Journal of Cancer Research and Clinical Oncology 137(11):1705-12, 2011 November
  40. Parker NR, Khong P, Parkinson JF, Howell VM, Wheeler HR.
    Molecular heterogeneity in glioblastoma: potential clinical implications.
    Frontiers in Oncology 5:55, 2015 Mar 3
  41. Chan DL, Schembri G, Back M, Bailey DL, Roach PJ, Wheeler H, Cook R, Parkinson J, Lee A, Jayamanne D, Drummond J, Hsiao E.
    FET PET in the evaluation of indeterminate brain lesions on MRI: differentiating glioma from other non-neoplastic causes.
    European Journal of Nuclear Medicine and Molecular Imaging 42:S603, 2015 Oct (Abstract)
  42. Parker NR, Hudson AL, Khong P, Parkinson JF, Dwight T, Ikin RJ, Zhu Y, Cheng ZJ, Vafaee F, Chen J, Wheeler HR, Howell VM.
    Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma.
    Scientific Reports 6:22477, 2016 Mar 4
  43. French H, Somasundaram A, Biggs M, Parkinson J, Allan R, Ball J, Little N.
    Idiopathic intradural dorsal thoracic arachnoid cysts: A case series and review of the literature.
    Journal of Clinical Neuroscience 40:147-152, 2017 Jun
  44. Harris G, Jayamanne D, Wheeler H, Gzell C, Kastelan M, Schembri G, Brazier D, Cook R, Parkinson J, Khasraw M, Louw S, Back M.
    Survival outcome of elderly patients with Glioblastoma Multiforme in their seventy fifth year or older treated with adjuvant therapy.
    International Journal of Radiation Oncology*Biology*Physics In press, Published online 2017 Feb 20